# SRRK catalysts: Scholar Rock Holding Corp PDUFA dates and FDA events

Canonical: https://sec-api.dev/companies/srrk/catalysts

> Scholar Rock Holding Corp (SRRK) has 4 upcoming catalysts. The next is the ISEMBYLD (apitegromab) primary completion, June 2028.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, exact day, quarter only, year only, half-year only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Company

| Field | Value |
| --- | --- |
| Name | Scholar Rock Holding Corp |
| Ticker | SRRK (Nasdaq) |
| SEC CIK | 1727196 |
| SIC | 2836 |
| SEC filings | https://sec-api.dev/companies/srrk |

## Cash runway

Cash $413.6M as of 2026-09-30; quarterly burn $81.8M; about 15.2 months of runway at that rate (XBRL company facts, accession 0001193125-26-454434).

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| Apr 2021 | [ISEMBYLD (apitegromab) topline data readout](https://sec-api.dev/pdufa/apitegromab) | SRRK |  | completed, positive | "Positive 12-month top-line results were initially announced in April 2021." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1727196/000155837024015155/srrk-20240930x10q.htm)) |
| Jan 2022 | [ISEMBYLD (apitegromab) trial start](https://sec-api.dev/pdufa/apitegromab) | SRRK | with Type 2 and Type 3 SMA and in October 2024, we | completed | "In January 2022, we initiated our Phase 3 SAPPHIRE clinical trial of apitegromab for the treatment of patients with Type 2 and Type 3 SMA and in October 2024, we announced positive top-line data from our Phase 3 SAPPHIRE clinical trial evaluating the efficacy and safety of apitegromab." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1727196/000155837025007655/srrk-20250331x10q.htm)) |
| Jan 2022 | [ISEMBYLD (apitegromab) topline data readout](https://sec-api.dev/pdufa/apitegromab) | SRRK | with Type 2 and Type 3 SMA and in October 2024, we | completed, positive | "In January 2022, we initiated our Phase 3 SAPPHIRE clinical trial of apitegromab for the treatment of patients with Type 2 and Type 3 SMA and in October 2024, we announced positive top-line data from our Phase 3 SAPPHIRE clinical trial evaluating the efficacy and safety of apitegromab." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1727196/000155837025007655/srrk-20250331x10q.htm)) |
| Oct 2023 | [ISEMBYLD (apitegromab) trial start](https://sec-api.dev/pdufa/apitegromab) | SRRK |  | completed | "We also announced in October 2023 our plans to expand into cardiometabolic disorders based on preclinical data with SRK-439, and we initiated the Phase 2 EMBRAZE proof-of-concept trial of" ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1727196/000155837025007655/srrk-20250331x10q.htm)) |
| October 7, 2024 | [ISEMBYLD (apitegromab) topline data readout](https://sec-api.dev/pdufa/apitegromab) | SRRK | non-ambulatory Type 2 and Type 3 SMA | completed, positive | "On October 7, 2024, we announced positive top-line data from our Phase 3 SAPPHIRE clinical trial evaluating the efficacy and safety of apitegromab in children and adults with SMA." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1727196/000110465926022551/srrk-20251231x10k.htm)) |
| November 12, 2024 | [Scholar Rock Holding Corp earnings report](https://sec-api.dev/companies/srrk/catalysts) | SRRK |  | completed | "Scholar Rock Reports Third Quarter 2024 Financial Results and Highlights Business Progress" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1727196/000155837024015149/srrk-20241112xex99d1.htm)) |
| Jan 2025 | [ISEMBYLD (apitegromab) NDA/BLA submission](https://sec-api.dev/pdufa/apitegromab) | SRRK | SMA, we | completed | "Prior to submitting the BLA to the U.S. FDA in January 2025 and submitting the MAA to the EMA in March 2025 for apitegromab as a treatment for patients with SMA, we had not submitted a BLA to the FDA or MAA to the EMA or similar marketing application to comparable foreign authorities." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1727196/000119312526454434/srrk-20260930.htm)) |
| Q1 2025 | [ISEMBYLD (apitegromab) NDA/BLA submission](https://sec-api.dev/pdufa/apitegromab) | SRRK |  | scheduled | "Based on these results, we plan to submit a BLA and MAA in the first quarter of 2025 and are working diligently to prepare for the commercial launch of apitegromab, and if approved, to deliver the potentially transformative benefits of apitegromab to children and adults living with SMA."" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1727196/000155837024015149/srrk-20241112xex99d1.htm)) |
| February 27, 2025 | [Scholar Rock Holding Corp earnings report](https://sec-api.dev/companies/srrk/catalysts) | SRRK |  | completed | "Scholar Rock Reports Full Year 2024 Financial Results and Highlights Business Progress" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1727196/000155837025001681/srrk-20250227xex99d1.htm)) |
| Mar 2025 | [ISEMBYLD (apitegromab) NDA/BLA acceptance](https://sec-api.dev/pdufa/apitegromab) | SRRK |  | completed | "In March 2025, the FDA accepted the Company's BLA for apitegromab for people with SMA and granted the application Priority Review with a" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1727196/000155837025007650/srrk-20250514xex99d1.htm)) |
| Q2 2025 | [Scholar Rock Holding Corp topline data readout](https://sec-api.dev/companies/srrk/catalysts) | SRRK |  | scheduled | "Enrollment completed ahead of schedule; topline data expected in Q2 2025" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1727196/000155837025000184/srrk-20250114xex99d1.htm)) |
| Q2 2025 | [ISEMBYLD (apitegromab) interim data readout](https://sec-api.dev/pdufa/apitegromab) | SRRK |  | scheduled | "Enrollment completed early with topline expected in Q2 2025" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1727196/000155837024015149/srrk-20241112xex99d2.htm)) |
| May 14, 2025 | [Scholar Rock Holding Corp earnings report](https://sec-api.dev/companies/srrk/catalysts) | SRRK |  | completed | "Scholar Rock Reports First Quarter 2025 Financial Results and Highlights Business Progress" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1727196/000155837025007650/srrk-20250514xex99d1.htm)) |
| June 18, 2025 | [ISEMBYLD (apitegromab) topline data readout](https://sec-api.dev/pdufa/apitegromab) | SRRK | obesity receiving tirzepatide | completed, positive | "On June 18, 2025, we announced positive top-line data from our Phase 2 EMBRAZE clinical trial evaluating apitegromab, an investigational muscle-targeted treatment, with tirzepatide to preserve lean mass during tirzepatide-induced weight loss." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1727196/000155837025010400/srrk-20250630x10q.htm)) |
| Q3 2025 | [ISEMBYLD (apitegromab) trial start](https://sec-api.dev/pdufa/apitegromab) | SRRK |  | scheduled | "The Company continues to develop apitegromab in SMA with its ongoing long-term extension ONYX trial and its plan to initiate the Phase 2 OPAL trial in SMA patients under two years of age in the third quarter of 2025." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1727196/000155837025010400/srrk-20250630x10q.htm)) |
| August 6, 2025 | [Scholar Rock Holding Corp earnings report](https://sec-api.dev/companies/srrk/catalysts) | SRRK |  | completed | "Scholar Rock Reports Second Quarter 2025 Financial Results and Highlights Business Progress" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1727196/000155837025010399/srrk-20250806xex99d1.htm)) |
| Sep 2025 | [Scholar Rock Holding Corp complete response letter (CRL)](https://sec-api.dev/companies/srrk/catalysts) | SRRK |  | completed, complete response letter | "In September 2025, we received a CRL from the FDA citing observations identified during an FDA inspection of a third-party fill-finish facility." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1727196/000119312526336732/srrk-20260630.htm)) |
| Sep 2025 | [ISEMBYLD (apitegromab) NDA/BLA acceptance](https://sec-api.dev/pdufa/apitegromab) | SRRK |  | completed | "We received a CRL from the FDA in September 2025 and in March 2026 we resubmitted the apitegromab BLA which was accepted by the FDA." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1727196/000119312526336732/srrk-20260630.htm)) |
| September 22, 2025 | [ISEMBYLD (apitegromab) PDUFA date](https://sec-api.dev/pdufa/apitegromab) | SRRK | Spinal Muscular Atrophy | completed, complete response letter | "Exhibit 99.1 target action date for apitegromab of September 22, 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1727196/000155837025010399/srrk-20250806xex99d1.htm)) |
| September 22, 2025 | [Isembyld (apitegromab-mstn) complete response letter (CRL)](https://sec-api.dev/pdufa/apitegromab-mstn) | SRRK |  | completed, complete response letter | "We have completed our review of this application and have determined that we cannot approve tl action be! his application in its present form." ([FDA complete response letter database](https://api.fda.gov/transparency/crl.json?search=file_name:%22CRL_BLA761463_20250922.pdf%22)) |
| September 23, 2025 | [ISEMBYLD (apitegromab) complete response letter (CRL)](https://sec-api.dev/pdufa/apitegromab) | SRRK |  | completed, complete response letter | "On September 23, 2025, the Company announced that the FDA has issued a CRL regarding the BLA for apitegromab for the treatment of SMA." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1727196/000110465925092317/tm2526733d1_8k.htm)) |
| November 14, 2025 | [Scholar Rock Holding Corp earnings report](https://sec-api.dev/companies/srrk/catalysts) | SRRK |  | completed | "Scholar Rock Reports Third Quarter 2025 Financial Results and Recent Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1727196/000110465925111931/srrk-20251114xex99d1.htm)) |
| Dec 2025 | [ISEMBYLD (apitegromab) trial start](https://sec-api.dev/pdufa/apitegromab) | SRRK |  | completed | "Dosing commenced in Phase 1 study in December 2025" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1727196/000110465926002757/srrk-20260112xex99d2.htm)) |
| 2026 | [ISEMBYLD (apitegromab) NDA/BLA submission](https://sec-api.dev/pdufa/apitegromab) | SRRK |  | scheduled | "Apitegromab BLA resubmission and U.S. launch, following approval, anticipated in 2026" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1727196/000110465926002757/srrk-20260112xex99d2.htm)) |
| March 3, 2026 | [Scholar Rock Holding Corp earnings report](https://sec-api.dev/companies/srrk/catalysts) | SRRK |  | completed | "Scholar Rock Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1727196/000110465926022547/srrk-20260303xex99d1.htm)) |
| March 31, 2026 | [ISEMBYLD (apitegromab) NDA/BLA submission](https://sec-api.dev/pdufa/apitegromab) | SRRK | children and adults with SMA | completed | "On March 31, 2026, Scholar Rock Holding Corporation (the "Company") issued a press release announcing it resubmitted its biologics license application ("BLA") to the U.S. Food and Drug Administration (the "FDA") for apitegromab for the treatment of children and adults with spinal muscular atrophy ("SMA")." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1727196/000110465926037350/tm2610664d1_8k.htm)) |
| mid-2026 | [ISEMBYLD (apitegromab) trial start](https://sec-api.dev/pdufa/apitegromab) | SRRK |  | scheduled | "The IND application is cleared, and the Company continues to anticipate the initiation of a Phase 2 randomized, double-blind, placebo-controlled trial, called FORGE, in mid-2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1727196/000110465926022547/srrk-20260303xex99d1.htm)) |
| May 7, 2026 | [Scholar Rock Holding Corp earnings report](https://sec-api.dev/companies/srrk/catalysts) | SRRK |  | completed | "Scholar Rock Reports First Quarter 2026 Financial Results and Recent Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1727196/000110465926056655/srrk-20260507xex99d1.htm)) |
| August 6, 2026 | [Scholar Rock Holding Corp earnings report](https://sec-api.dev/companies/srrk/catalysts) | SRRK |  | completed | "Scholar Rock Reports Second Quarter 2026 Financial Results and Recent Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1727196/000119312526336715/srrk-ex99_1.htm)) |
| September 11, 2026 | [ISEMBYLD (apitegromab) FDA approval](https://sec-api.dev/pdufa/apitegromab) | SRRK | SMA in adults and children 2 years of age and older | completed, approved | "On September 11, 2026, the Company announced that the FDA has approved ISEMBYLD™ (apitegromab-mstn) for the treatment of SMA in adults and children 2 years of age and older who are currently receiving a survival SMN2 targeted treatment." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1727196/000110465926107273/tm2625362d1_8k.htm)) |
| September 11, 2026 | [Isembyld (apitegromab-mstn) FDA approval](https://sec-api.dev/pdufa/apitegromab-mstn) | SRRK |  | completed, approved | "Isembyld \| apitegromab-mstn \| 9/11/2026 \| To treat spinal muscular atrophy in adults and pediatric patients 2 years of age and older who are currently receiving an SMN2-targeted treatment" ([FDA novel drug approvals](https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2026)) |
| September 30, 2026 | [ISEMBYLD (apitegromab) PDUFA date](https://sec-api.dev/pdufa/apitegromab) | SRRK |  | completed, approved | "Apitegromab Biologics License Application (BLA) for spinal muscular atrophy (SMA) review by FDA continues to advance with two fill-finish facilities, representing two independent paths to an FDA approval decision by September 30, 2026 Prescription Drug User Fee Act (PDUFA) date" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1727196/000119312526336715/srrk-ex99_1.htm)) |
| November 2026 | [ISEMBYLD (apitegromab) primary completion](https://sec-api.dev/pdufa/apitegromab) | SRRK | Spinal Muscular Atrophy; Spinal Muscular Atrophy Type 3; Spinal Muscular Atrophy Type 2 | scheduled | "NCT05626855 (Long-Term Safety & Efficacy of Apitegromab in Patients With SMA Who Completed Previous Trials of Apitegromab): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-11-01 (ESTIMATED); Lead Sponsor Scholar Rock, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05626855)) |
| Nov 2026 to Feb 2027 | [ISEMBYLD (apitegromab) topline data readout](https://sec-api.dev/pdufa/apitegromab) | SRRK | Spinal Muscular Atrophy; Spinal Muscular Atrophy Type 3; Spinal Muscular Atrophy Type 2 | scheduled | "NCT05626855 (Long-Term Safety & Efficacy of Apitegromab in Patients With SMA Who Completed Previous Trials of Apitegromab): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-11-01 (ESTIMATED); Lead Sponsor Scholar Rock, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05626855)) |
| November 10, 2026 | [Scholar Rock Holding Corp earnings report](https://sec-api.dev/companies/srrk/catalysts) | SRRK |  | completed | "Scholar Rock Reports Third Quarter 2026 Financial Results and Recent Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1727196/000119312526454423/srrk-ex99_1.htm)) |
| June 2028 | [ISEMBYLD (apitegromab) primary completion](https://sec-api.dev/pdufa/apitegromab) | SRRK | Facioscapulohumeral Muscular Dystrophy; FSHD | scheduled | "NCT07435129 (Phase 2 Study Evaluating Apitegromab for the Treatment of FSHD): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-06 (ESTIMATED); Lead Sponsor Scholar Rock, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07435129)) |
| Jun to Sep 2028 | [ISEMBYLD (apitegromab) topline data readout](https://sec-api.dev/pdufa/apitegromab) | SRRK | Facioscapulohumeral Muscular Dystrophy; FSHD | scheduled | "NCT07435129 (Phase 2 Study Evaluating Apitegromab for the Treatment of FSHD): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-06 (ESTIMATED); Lead Sponsor Scholar Rock, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07435129)) |
| November 2028 | [ISEMBYLD (apitegromab) primary completion](https://sec-api.dev/pdufa/apitegromab) | SRRK | Spinal Muscular Atrophy; SMA; Spinal Muscular Atrophy Type 2 | scheduled | "NCT07047144 (A Study to Evaluate How Apitegromab Works in Subjects Who Are Less Than 2 Years Old and Have Spinal Muscular Atrophy): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-11 (ESTIMATED); Lead Sponsor Scholar Rock, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07047144)) |
| Nov 2028 to Feb 2029 | [ISEMBYLD (apitegromab) topline data readout](https://sec-api.dev/pdufa/apitegromab) | SRRK | Spinal Muscular Atrophy; SMA; Spinal Muscular Atrophy Type 2 | scheduled | "NCT07047144 (A Study to Evaluate How Apitegromab Works in Subjects Who Are Less Than 2 Years Old and Have Spinal Muscular Atrophy): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-11 (ESTIMATED); Lead Sponsor Scholar Rock, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07047144)) |

## Drugs

- [ISEMBYLD (apitegromab)](https://sec-api.dev/pdufa/apitegromab): sma, we, non-ambulatory type 2 and type 3 sma, with type 2 and type 3 sma and in october 2024, we, obesity, children and adults with sma, nonambulatory type 2 and type 3 sma, Spinal Muscular Atrophy, Facioscapulohumeral Muscular Dystrophy
- [Isembyld (apitegromab-mstn)](https://sec-api.dev/pdufa/apitegromab-mstn): 

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/companies/srrk/catalysts.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "SRRK catalysts: Scholar Rock Holding Corp PDUFA dates and FDA events." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/companies/srrk/catalysts

```bibtex
@misc{secapidev_companies_srrk_catalysts_20261116,
  title        = {SRRK catalysts: Scholar Rock Holding Corp PDUFA dates and FDA events},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/companies/srrk/catalysts}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_companies_srrk_catalysts_20261116","title":"SRRK catalysts: Scholar Rock Holding Corp PDUFA dates and FDA events","publisher":"sec-api.dev","URL":"https://sec-api.dev/companies/srrk/catalysts","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
